Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study

被引：16

作者：

Alten, Rieke ^{[1
]}

Nuesslein, Hubert ^{[2
]}

Galeazzi, Mauro ^{[3
]}

Lorenz, Hanns-Martin ^{[4
]}

Nurmohamed, Michael T. ^{[5
]}

Bensen, William G. ^{[6
,7
]}

Burmester, Gerd R. ^{[8
]}

Peter, Hans-Hartmut ^{[9
]}

Pavelka, Karel ^{[10
,11
]}

Chartier, Melanie ^{[12
]}

Poncet, Coralie ^{[13
]}

Rauch, Christiane ^{[14
]}

Elbez, Yedid ^{[15
]}

Le Bars, Manuela ^{[16
]}

机构：

[1] Univ Med, Schlosspk Klin, Dept Rheumatol, Berlin, Germany

[2] Univ Erlangen Nurnberg, Dept Clin Immunol & Rheumatol, Nurnberg, Germany

[3] Univ Siena, Dept Rheumatol, Siena, Italy

[4] Univ Hosp, Dept Rheumatol, Heidelberg, Germany

[5] Vrije Univ Amsterdam Med Ctr, Jan van Breemen Res Inst, Dept Rheumatol, Amsterdam, Netherlands

[6] St Josephs Hosp, Dept Rheumatol, Hamilton, ON, Canada

[7] McMaster Univ, Hamilton, ON, Canada

[8] Charite, Dept Rheumatol & Immunol, Berlin, Germany

[9] Univ Med Ctr, Ctr Chron Immunodeficiency, Freiburg, Germany

[10] Charles Univ Prague, Inst Rheumatol, Prague, Czech Republic

[11] Charles Univ Prague, Clin Rheumatol, Prague, Czech Republic

[12] Chiltern Int, Dept Real World Res, Neuilly, France

[13] DOCS Int, Dept Biostat, Nanterre, France

[14] Bristol Myers Squibb Co, Dept Med Immunosci, Munich, Germany

[15] Excelya, Boulogne, France

[16] Bristol Myers Squibb Co, Dept Med Affairs, Rueil Malmaison, France

来源：

RMD OPEN | 2016年 / 2卷 / 01期

关键词：

D O I：

10.1136/rmdopen-2015-000228

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

Introduction: Prolonged glucocorticoid use may increase the risk of adverse safety outcomes, including cardiovascular events. The European League Against Rheumatism and the Canadian Rheumatology Association advise tapering glucocorticoid dose as rapidly as clinically feasible. There is a paucity of published data on RA that adequately describe concomitant treatment patterns. Methods: ACTION (AbataCepT In rOutiNe clinical practice) is a non-interventional cohort study of patients from Europe and Canada that investigated the long-term retention of intravenous abatacept in clinical practice. We assessed concomitant glucocorticoids in patients with established RA who had participated in ACTION and received >= 1 biological agent prior to abatacept initiation. Results: The analysis included 1009 patients. Glucocorticoids were prescribed at abatacept initiation in 734 (72.7%) patients at a median 7.5 mg/day dose (n=692). Of the patients who remained on abatacept at 24 months, 40.7% were able to decrease their dose of glucocorticoids, including 26.9% who decreased their dose from >5 mg/day to <= 5 mg/day. Conclusion: Reduction and/or cessation of glucocorticoid therapy is possible with intravenous abatacept in clinical practice.

引用

页数：4

共 11 条

[1]

Information on glucocorticoid therapy in the main studies of biological agents [J].

Andre, Vincent ;

le Goff, Benoit ;

Leux, Christophe ;

Pot-Vaucel, Marianne ;

Maugars, Yves ;

Berthelot, Jean-Marie .

JOINT BONE SPINE, 2011, 78 (05) :478-483

[2]

Canadian Rheumatology Association Recommendations for Pharmacological Management of Rheumatoid Arthritis with Traditional and Biologic Disease-modifying Antirheumatic Drugs [J].

Bykerk, Vivian P. ;

Akhavan, Pooneh ;

Hazlewood, Glen S. ;

Schieir, Orit ;

Dooley, Anne ;

Haraoui, Boulos ;

Khraishi, Majed ;

Leclercq, Sharon A. ;

Legare, Jean ;

Mosher, Diane P. ;

Pencharz, James ;

Pope, Janet E. ;

Thomson, John ;

Thorne, Carter ;

Zummer, Michel ;

Bombardier, Claire .

JOURNAL OF RHEUMATOLOGY, 2012, 39 (08) :1559-1582

[3]

Fernandez-Nebro A, 2007, J RHEUMATOL, V34, P2334

[4]

Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly [J].

Galloway, James B. ;

Hyrich, Kimme L. ;

Mercer, Louise K. ;

Dixon, William G. ;

Fu, Bo ;

Ustianowski, Andrew P. ;

Watson, Kath D. ;

Lunt, Mark ;

Symmons, Deborah P. M. .

RHEUMATOLOGY, 2011, 50 (01) :124-131

[5]

Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry [J].

Hetland, M. L. ;

Lindegaard, H. M. ;

Hansen, A. ;

Podenphant, J. ;

Unkerskov, J. ;

Ringsdal, V. S. ;

Ostergaard, M. ;

Tarp, U. .

ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (07) :1023-1026

[6]

TNF-α Antagonist Survival Rate in a Cohort of Rheumatoid Arthritis Patients Observed under Conditions of Standard Clinical Practice [J].

Marchesoni, Antonio ;

Zaccara, Eleonora ;

Gorla, Roberto ;

Bazzani, Chiara ;

Sarzi-Puttini, Piercarlo ;

Atzeni, Fabiola ;

Caporali, Roberto ;

Bobbio-Pallavicini, Francesca ;

Favalli, Ennio Giulio .

CONTEMPORARY CHALLENGES IN AUTOIMMUNITY, 2009, 1173 :837-846

[7]

Anti-tumour necrosis factor α therapy in patients with rheumatoid arthritis results in a significant and long-lasting decrease of concomitant glucocorticoid treatment [J].

Naumann, L. ;

Huscher, D. ;

Detert, J. ;

Spengler, M. ;

Burmester, G-R ;

Buttgereit, F. .

ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (12) :1934-1936

[8]

Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study [J].

Nuesslein, Hubert G. ;

Alten, Rieke ;

Galeazzi, Mauro ;

Lorenz, Hanns-Martin ;

Boumpas, Dimitrios ;

Nurmohamed, Michael T. ;

Bensen, William G. ;

Burmester, Gerd R. ;

Peter, Hans-Hartmut ;

Rainer, Franz ;

Pavelka, Karel ;

Chartier, Melanie ;

Poncet, Coralie ;

Rauch, Christiane ;

Le Bars, Manuela .

BMC MUSCULOSKELETAL DISORDERS, 2014, 15

[9]

The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis [J].

Roubille, Camille ;

Richer, Vincent ;

Starnino, Tara ;

McCourt, Collette ;

McFarlane, Alexandra ;

Fleming, Patrick ;

Siu, Stephanie ;

Kraft, John ;

Lynde, Charles ;

Pope, Janet ;

Gulliver, Wayne ;

Keeling, Stephanie ;

Dutz, Jan ;

Bessette, Louis ;

Bissonnette, Robert ;

Haraoui, Boulos .

ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (03) :480-489

[10]

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update [J].

Smolen, Josef S. ;

Landewe, Robert ;

Breedveld, Ferdinand C. ;

Buch, Maya ;

Burmester, Gerd ;

Dougados, Maxime ;

Emery, Paul ;

Gaujoux-Viala, Cecile ;

Gossec, Laure ;

Nam, Jackie ;

Ramiro, Sofia ;

Winthrop, Kevin ;

de Wit, Maarten ;

Aletaha, Daniel ;

Betteridge, Neil ;

Bijlsma, Johannes W. J. ;

Boers, Maarten ;

Buttgereit, Frank ;

Combe, Bernard ;

Cutolo, Maurizio ;

Damjanov, Nemanja ;

Hazes, Johanna M. W. ;

Kouloumas, Marios ;

Kvien, Tore K. ;

Mariette, Xavier ;

Pavelka, Karel ;

van Riel, Piet L. C. M. ;

Rubbert-Roth, Andrea ;

Scholte-Voshaar, Marieke ;

Scott, David L. ;

Sokka-Isler, Tuulikki ;

Wong, John B. ;

van der Heijde, Desiree .

ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (03) :492-509

← 1 2 →